Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

MicroRNAs in Myeloid Hematological Malignancies.

Ciccone M, Calin GA.

Curr Genomics. 2015 Oct;16(5):336-48. doi: 10.2174/138920291605150710122815.

2.

MiR181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression.

Yao L, Wang L, Li F, Gao X, Wei X, Liu Z.

Int J Clin Exp Med. 2015 Sep 15;8(9):15198-205. eCollection 2015.

3.

miRNAs as Biomarkers in Chronic Myelogenous Leukemia.

Kotagama K, Chang Y, Mangone M.

Drug Dev Res. 2015 Sep;76(6):278-85. doi: 10.1002/ddr.21266. Epub 2015 Aug 18.

4.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

5.

MicroRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells.

Wang H, Li J, Chi H, Zhang F, Zhu X, Cai J, Yang X.

J Cell Mol Med. 2015 Sep;19(9):2084-97. doi: 10.1111/jcmm.12563. Epub 2015 Apr 20.

6.

MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.

Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X, Guo H.

Oncotarget. 2015 Apr 20;6(11):8914-28.

7.

Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.

Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G.

PLoS One. 2014 Apr 1;9(4):e93404. doi: 10.1371/journal.pone.0093404. eCollection 2014.

8.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

9.

Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.

Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, Distelhorst CW, Lathia JD, Rich JN, Kappes JC, Gladson CL.

PLoS One. 2013 Aug 2;8(8):e70804. doi: 10.1371/journal.pone.0070804. Print 2013.

10.

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.

Mosakhani N, Mustjoki S, Knuutila S.

Mol Cytogenet. 2013 Jul 16;6(1):27. doi: 10.1186/1755-8166-6-27.

11.

Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM.

PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013.

12.

The role of microRNAs in B-cell development and function.

Li J, Wan Y, Ji Q, Fang Y, Wu Y.

Cell Mol Immunol. 2013 Mar;10(2):107-12. doi: 10.1038/cmi.2012.62. Epub 2013 Jan 14. Review.

13.

Specific Roles of MicroRNAs in Their Interactions with Environmental Factors.

Wang J, Cui Q.

J Nucleic Acids. 2012;2012:978384. doi: 10.1155/2012/978384. Epub 2012 Oct 31.

14.

microRNAs: innovative targets for cerebral ischemia and stroke.

Ouyang YB, Stary CM, Yang GY, Giffard R.

Curr Drug Targets. 2013 Jan 1;14(1):90-101. Review.

15.

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.

Stamelos VA, Redman CW, Richardson A.

J Mol Signal. 2012 Aug 16;7(1):12. doi: 10.1186/1750-2187-7-12.

16.

Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes.

Hanin G, Soreq H.

Front Mol Neurosci. 2011 Oct 5;4:28. doi: 10.3389/fnmol.2011.00028. eCollection 2011.

17.

miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes.

Ouyang YB, Lu Y, Yue S, Giffard RG.

Mitochondrion. 2012 Mar;12(2):213-9. doi: 10.1016/j.mito.2011.09.001. Epub 2011 Sep 17.

18.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

Items per page

Supplemental Content

Write to the Help Desk